PFIZER INC.

Moderna has settled patent infringement lawsuits filed by Alnylam Pharmaceuticals over alleged misuse of lipid nanoparticle technology in COVID-19 vaccines.

CatalYm appointed four experienced executives to accelerate visugromab's progression into late-stage clinical development following promising Phase 2a results.

Pfizer's PF-07248144, a first-in-class KAT6 inhibitor discovered by Australian researchers, has commenced Phase 3 clinical trials for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

The FDA plans to present data at next week's CDC Advisory Committee on Immunization Practices meeting claiming to link COVID-19 vaccines to 25 deaths in children, based on analysis of VAERS database reports.

Enveda Biosciences secured $150 million in Series D funding led by Premji Invest to advance its AI-powered drug discovery platform that mines natural molecules for therapeutic development.

Democratic governors from Washington, California, and Oregon announced the creation of the West Coast Health Alliance to provide unified, evidence-based public health recommendations amid concerns over CDC politicization.

Radiance Biopharma has signed an exclusive licensing agreement with Novatim for RB-601™, a first-in-class bispecific nanobody ADC targeting c-MET and EGFR receptors.

Biohaven's Vyglxia could become the first approved treatment for spinocerebellar ataxia, a rare genetic brain disorder affecting movement and coordination, with FDA decision expected between October and December.

Olema Oncology and Pfizer have announced a new clinical trial collaboration to evaluate the combination of palazestrant and atirmociclib in approximately 35 patients with ER+/HER2- metastatic breast cancer.

The FDA approved Pfizer-BioNTech's LP.8.1-adapted monovalent COVID-19 vaccine on August 27 for adults 65 and older and individuals aged 5-64 with high-risk conditions.